Form 4: Quest Diagnostics Director Robert B. Carter Reports Stock Award and Disposal

Director Robert B. Carter reports acquisition of 1,203 shares of common stock and disposal of 2,685 shares.

Summary

• On May 15, 2025, Robert B. Carter, a director of Quest Diagnostics Inc., reported a transaction involving the company's common stock.
• Carter acquired 1,203 shares of common stock through an award.
• Carter disposed of 2,685 shares of common stock.
• Following the reported transactions, Carter beneficially owns 2,685 shares of Quest Diagnostics Inc.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports transactions without providing explicit positive or negative outlook.

Positives

• The acquisition of restricted stock units suggests confidence in the company's future performance.

Negatives

• The disposal of 2,685 shares could be interpreted negatively by investors, although the reason for disposal is not specified.

Risks

• Unspecified reasons for stock disposal could lead to investor speculation and potential market volatility.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• The stock transactions of a director can influence investor sentiment and potentially affect the stock price.

Key Dates

Keywords

Quest Diagnostics, Director, Robert B. Carter, Stock, Acquisition, Disposal, Restricted Stock Units, DGX